These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36778871)

  • 1. Novel TLR7/8 agonists promote activation of HIV-1 latent reservoirs and human T and NK cells.
    Li Y; Wang Z; Hou Y; Liu X; Hong J; Shi X; Huang X; Zhang T; Liao X; Zhang L
    Front Microbiol; 2023; 14():1033448. PubMed ID: 36778871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
    Tsai A; Irrinki A; Kaur J; Cihlar T; Kukolj G; Sloan DD; Murry JP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accessory-cell-mediated activation of porcine NK cells by toll-like receptor 7 (TLR7) and TLR8 agonists.
    Toka FN; Nfon CK; Dawson H; Golde WT
    Clin Vaccine Immunol; 2009 Jun; 16(6):866-78. PubMed ID: 19369481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR8 activates HIV from latently infected cells of myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-α.
    Schlaepfer E; Speck RF
    J Immunol; 2011 Apr; 186(7):4314-24. PubMed ID: 21357269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
    Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
    J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HIV activity mediated by natural killer and CD8+ cells after toll-like receptor 7/8 triggering.
    Schlaepfer E; Speck RF
    PLoS One; 2008 Apr; 3(4):e1999. PubMed ID: 18431484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.
    Beesu M; Salyer AC; Brush MJ; Trautman KL; Hill JK; David SA
    J Med Chem; 2017 Mar; 60(5):2084-2098. PubMed ID: 28146629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
    Kandimalla ER; Struthers M; Bett AJ; Wisniewski T; Dubey SA; Jiang W; Precopio M; Sun Z; Wang H; Lan T; Agrawal S; Casimiro DR
    Cell Immunol; 2011; 270(2):126-34. PubMed ID: 21570062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.
    Rochat MA; Schlaepfer E; Speck RF
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An assessment of toll-like receptor 7 and 8 gene polymorphisms with susceptibility to HIV-1 infection, AIDS development and response to antiretroviral therapy.
    Zaidane I; Ouladlahsen A; Bensghir R; Chihab H; Jadid FZ; Fɩhry RE; Baba H; Filali KME; Oudghiri M; Wakrim L; Benjelloun S; Ezzikouri S
    Immunol Lett; 2020 Nov; 227():88-95. PubMed ID: 32888973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
    Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR7/TLR8 Activation Restores Defective Cytokine Secretion by Myeloid Dendritic Cells but Not by Plasmacytoid Dendritic Cells in HIV-Infected Pregnant Women and Newborns.
    Cardoso EC; Pereira NZ; Mitsunari GE; Oliveira LM; Ruocco RM; Francisco RP; Zugaib M; da Silva Duarte AJ; Sato MN
    PLoS One; 2013; 8(6):e67036. PubMed ID: 23826189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
    Hamm S; Rath S; Michel S; Baumgartner R
    J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.
    Gorden KB; Gorski KS; Gibson SJ; Kedl RM; Kieper WC; Qiu X; Tomai MA; Alkan SS; Vasilakos JP
    J Immunol; 2005 Feb; 174(3):1259-68. PubMed ID: 15661881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma.
    Zhou Z; Yu X; Zhang J; Tian Z; Zhang C
    Cancer Lett; 2015 Dec; 369(2):298-306. PubMed ID: 26433159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
    Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
    Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes.
    Nian H; Geng WQ; Cui HL; Bao MJ; Zhang ZN; Zhang M; Pan Y; Hu QH; Shang H
    BMC Infect Dis; 2012 Jan; 12():5. PubMed ID: 22243920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7.
    Lai CY; Liu YL; Yu GY; Maa MC; Leu TH; Xu C; Luo Y; Xiang R; Chuang TH
    Vaccine; 2014 Sep; 32(43):5593-9. PubMed ID: 25131730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent
    Bardhi A; Wu Y; Chen W; Li W; Zhu Z; Zheng JH; Wong H; Jeng E; Jones J; Ochsenbauer C; Kappes JC; Dimitrov DS; Ying T; Goldstein H
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.
    Rong L; Perelson AS
    PLoS Comput Biol; 2009 Oct; 5(10):e1000533. PubMed ID: 19834532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.